The human antigen R as an actionable super-hub within the network of cancer cell persistency and plasticity

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Solid cancers adapt to targeted therapies through mechanisms involving cell plasticity.
• Emergence of dedifferentiated, slow-proliferating cancer cells poses a therapeutic challenge.
• Understanding post-transcriptional regulation is crucial for overcoming treatment resistance.

Purpose of the Study:

• To present a phenotype-driven experimental approach for studying cancer adaptive responses.
• To discover druggable mechanisms that prevent the emergence of plastic, dedifferentiated cancer cells.
• To illustrate this approach using BRAFV600-melanoma and BRAF inhibition.

Main Methods:

• Clinically inspired, phenotype-driven experimental design.
• Quantitative assessment of cell plasticity.
• Information theory-based detection of in vivo dependencies.
• Investigation of post-transcriptional regulatory mechanisms.

Main Results:

• Identified the interferon-γ-activated inhibitor of translation (GAIT) complex as a key regulator.
• Demonstrated that GAIT complex inhibition, linked to insufficient RNA-binding protein HuR, suppresses plastic cells.
• Developed a therapeutic strategy targeting GAIT complex activity in BRAFV600-melanoma.

Conclusions:

• The proposed approach effectively identifies targets to overcome adaptive resistance in solid cancers.
• Modulating the GAIT complex and HuR expression offers a potential strategy against therapy-resistant cells.
• This framework can be applied to validate other mechanisms for improved cancer treatment.